A Phase 1/2 interventional study of Mosunetuzumab SC and Tiragolumab in Non-Hodgkin Lymphoma, Follicular Lymphoma, sponsored by Hoffmann-La Roche. Terminated at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-04.
Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing mosunetuzumab in Lymphoma, Follicular — 8 open to participants now, 15 under way, 3 of them phase 3. mosunetuzumab · Lymphoma, Follicular.
Among the 17 studies testing mosunetuzumab in Lymphoma, Follicular, this one is the 17th largest by enrollment, is one of 6 that started in 2022, is one of 2 in phase 1/2, and was the 5th registered.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
Browse Lymphoma, Follicular studies →8 of the 17 studies testing mosunetuzumab in Lymphoma, Follicular are open now, in 3 countries. Recruiting first, the newest first:
University of Washington · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
Oslo University Hospital · Sites in Finland, Norway
Ages 18+
By country, each count listing its studies:
mosunetuzumab: first FDA approval 2022 (LUNSUMIO VELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 3
First in 2020; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Median enrollment 42 across the 17 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 17 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
22 studies in Lymphoma, Follicular by Hoffmann-La Roche: none open now, 2 under way, 1 of them phase 3. Of 20 finished, 16 (80%) have results posted.
Among the 22 studies in Lymphoma, Follicular by Hoffmann-La Roche, this one is the 14th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 1/2, and was the 22nd registered.
Hoffmann-La Roche’s Lymphoma, Follicular studies by the year they started, since 2004.
4 of the studies testing mosunetuzumab in Lymphoma, Follicular that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05849857Oslo University HospitalMosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries | 2027-06 |
| NCT07031700Tianjin Medical University Cancer Institute and HospitalA Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL | 2027-06-30 |
| NCT06442475University of WashingtonLow Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma | 2027-08-12 |
| NCT04792502Brown UniversityMosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing mosunetuzumab in Lymphoma, Follicular, from their registry updates:
Among Hoffmann-La Roche’s 22 in Lymphoma, Follicular:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety, efficacy, and pharmacokinetics of mosunetuzumab in combination with tiragolumab, with or without atezolizumab, in participants with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) who have received at least two previous lines of systemic therapy.
1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.
This study's enrollment of 8 is below the median of 48 across 1,503 interventional studies indexed under Lymphoma, Follicular.
Browse Lymphoma, Follicular studies →Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Compared within Lymphoma, Follicular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days)
Drug: Mosunetuzumab SC · Drug: Tiragolumab · Other: Tocilizumab
Participants will receive at least 8 and up to 17 cycles of treatment (cycle length = 21 days) Note: This arm did not enroll any participants.
Drug: Mosunetuzumab SC · Drug: Tiragolumab · Drug: Atezolizumab · Other: Tocilizumab
Participants will receive SC mosunetuzumab for up to 17 treatment cycles (cycle length = 21 days)
Participants will receive IV tiragolumab every 3 weeks (Q3W) for up to 17 treatment cycles (cycle length = 21 days)
Participants will receive IV atezolizumab Q3W for up to 17 treatment cycles (cycle length = 21 days)
Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS) events
Percentage of Participants With Adverse Events - Phase 1b
Time frame: From the start of treatment until 90 days after the final dose of study treatment (up to 36 weeks)
Best Objective Response Rate (ORR) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 2
Time frame: Up to Cycle 17 (cycle length = 21 days)
Best ORR as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b
Best ORR is defined as the fraction of participants with complete response (CR) or partial response (PR) at any time as determined by the investigator using Lugano 2014 criteria.
Time frame: Assessed at screening and then every 3-6 months until disease progression, start of new anti-cancer therapy, or withdrawal (through Cycle 8; cycle length = 21 days)
Serum Concentration of Mosunetuzumab - Phase 1b
Time frame: Cycle 1 Day 1 - Cycle 8 Day 1 (cycle length = 21 days)
Best Complete Response (CR) Rate as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b
Time frame: Assessed at screening and then every 3-6 months until disease progression, start of new anti-cancer therapy, or withdrawal (through Cycle 8; cycle length = 21 days)
Duration of Response (DOR) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b and Phase 2
Time frame: From the first occurrence of a documented response (CR or partial response (PR)) to disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 4 years)
Progression-Free Survival (PFS) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 2
Time frame: From the first study treatment to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 4 years)
Event-Free Survival (EFS) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 2
Time frame: From the first study treatment to the first occurrence of disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 4 years)
Overall Survival (OS) - Phase 2
Time frame: From the time of first study treatment to death from any cause (up to approximately 4 years)
Percentage of Participants With Adverse Events - Phase 2
Time frame: From the start of treatment until 90 days after the final dose of study treatment
| Milestone | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| Started | 8 |
| Completed | 0 |
| Not completed | 8 |
| Withdrew: Death | 5 |
| Withdrew: Progressive disease | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Study terminated by sponsor | 1 |
| Percentage of participants | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| Percentage of Participants With Adverse Events - Phase 1b | 100 |
No measurements were reported for this outcome.
Best ORR is defined as the fraction of participants with complete response (CR) or partial response (PR) at any time as determined by the investigator using Lugano 2014 criteria.
| Percentage of participants | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| Best ORR as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b | 62.5 |
| ug/mL | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| C1D1 pre-dose | NA ± NA |
| C1D1 3 hrs post-dose | 0.00983 ± NA |
| C1D2 24 hrs post-dose | 0.0556 ± 109.6 |
| C1D4 72 hrs post-dose | 0.164 ± 90.5 |
| C1D8 pre-dose | 0.166 ± 83.2 |
| C1D15 pre-dose | 2.18 ± 48.8 |
| C2D1 pre-dose | 4.02 ± 86.3 |
| C3D1 pre-dose | 2.90 ± 81.8 |
| C4D1 pre-dose | 2.34 ± 49.0 |
| C4D1 3 hrs post-dose | 2.10 ± 48.2 |
| C5D1 pre-dose | 2.59 ± 25.7 |
| C8D1 pre-dose | 2.97 ± 17.7 |
| Percentage of participants | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| Best Complete Response (CR) Rate as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b | 37.5 |
| Time | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| Duration of Response (DOR) as Determined by the Investigator Using Lugano 2014 Criteria - Phase 1b and Phase 2 | NA |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over From the start of treatment until 90 days after the final dose of study treatment (up to 36 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab | 5/8 (62.5%) | 2/8 (25%) | 8/8 (100%) |
| Event | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| Abdominal painGastrointestinal disorders | 1/8 |
| DiarrhoeaGastrointestinal disorders | 1/8 |
| COVID-19Infections and infestations | 1/8 |
| Pneumonia aspirationInfections and infestations | 1/8 |
| Septic shockInfections and infestations | 1/8 |
| FallInjury, poisoning and procedural complications | 1/8 |
| Cerebellar haematomaNervous system disorders | 1/8 |
| Event | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 3/8 |
| Injection site reactionGeneral disorders | 3/8 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/8 |
| NeutropeniaBlood and lymphatic system disorders | 2/8 |
| ConstipationGastrointestinal disorders | 2/8 |
| NauseaGastrointestinal disorders | 2/8 |
| AstheniaGeneral disorders | 2/8 |
| Oedema peripheralGeneral disorders | 2/8 |
| HypokalaemiaMetabolism and nutrition disorders | 2/8 |
| HypophosphataemiaMetabolism and nutrition disorders | 2/8 |
| Age, Continuous(Years) | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| Mean | 64.9 ± 12.8 |
| Sex: Female, Male(Participants) | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| Female | 4 |
| Male | 4 |
| Ethnicity (NIH/OMB)(Participants) | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 2 |
| Race (NIH/OMB)(Participants) | Subcutaneous (SC) Mosunetuzumab in Combination With Intravenous (IV) Tiragolumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 6 |
| More than one race | 0 |
| Unknown or Not Reported | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from May 2022 to primary completion in Jul 2023, 14 months.
Results were first posted in Oct 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Mosunetuzumab · Tiragolumab